
I maintain my Buy rating of Oklo with my price target revised from $99 to $88 due to dilution. Q2 2026 demonstrated tangible execution progress: Groves achieved first criticality, Aurora-INL advanced, and Aurora-Ohio secured key agreements. My normalized EBITDA estimate rises modestly to $443 million, with improved confidence in risk-adjusted capacity for Ohio, INL, Fuel, and Isotopes.










